Document:

Exhibit 10.2

 

WARRANT EXERCISE AGREEMENT

 

This Warrant Exercise Agreement (this “Agreement”),
dated as of May 14, 2018, is by and between TapImmune Inc., a Nevada corporation (the “Company”) and the undersigned
holder (the “Holder”) of those certain (i) Series D Warrant to Purchase Common Stock issued by the Company to
the Holder, which warrant is exercisable at an exercise price (the “Series D Warrant Exercise Price”) of $9.00
per share (the “Series D Warrant”); (ii) Series E Warrant to Purchase Common Stock issued by the Company to
the Holder, which warrant is exercisable at an exercise price (the “Series E Warrant Exercise Price”) of $15.00
per share (the “Series E Warrant”); and (iii) Series F Warrant to Purchase Common Stock issued by the Company
to the Holder, which warrant is exercisable at an exercise price (the “Series F Warrant Exercise Price”) of
$7.20 per share (the “Series F Warrant”).

 

WHERAS, the Holder’s Series D Warrant
is exercisable for a number of shares of common stock, par value $0.001 per share, of the Company (the “Common Stock”)
as set forth on such Holder’s signature page hereto (the “Series D Warrant Shares”) and the Holder desires
to fully exercise such Series D Warrant and, immediately prior to such exercise and in consideration of the Holder’s agreement
to so exercise such Series D Warrant, the Company has agreed to reduce the Series D Warrant Exercise Price to $2.50 per share (the
“Revised Series D Warrant Exercise Price”); and

 

WHERAS, the Holder’s Series E Warrant
is exercisable for a number of shares of Common Stock as set forth on such Holder’s signature page hereto (the “Series
E Warrant Shares”) and the Holder desires to fully exercise such Series E Warrant and, immediately prior to such exercise
and in consideration of the Holder’s agreement to so exercise such Series E Warrant, the Company has agreed to reduce the
Series E Warrant Exercise Price to $2.50 per share (the “Revised Series E Warrant Exercise Price”).

 

WHERAS, the Holder’s Series F Warrant
is exercisable for a number of shares of Common Stock as set forth on such Holder’s signature page hereto (the “Series
F Warrant Shares”) and the Holder desires to fully exercise such Series F Warrant and, immediately prior to such exercise
and in consideration of the Holder’s agreement to so exercise such Series F Warrant, the Company has agreed to reduce the
Series F Warrant Exercise Price to $2.50 per share (the “Revised Series F Warrant Exercise Price”).

 

NOW, THEREFORE, IN CONSIDERATION of the
mutual covenants contained in this Agreement, and for good and valuable consideration the receipt and adequacy of which are hereby
acknowledged, the Holder and the Company agree as follows:

 

ARTICLE I

DEFINITIONS

 

Section 1.1 Definitions.
Capitalized terms not defined in this Agreement shall have the respective meanings ascribed to such terms in the Series D Warrant,
Series E Warrant and Series F Warrant.

 

ARTICLE II

EXERCISE OF WARRANTS; 

REDUCTION OF EXERCISE PRICES OF WARRANTS;
CLOSING

  

Section 2.1 Exercise of Series
D Warrant. Subject to the satisfaction (or waiver) of the closing conditions set forth in Article IV hereof, upon the Closing,
the Company and the Holder hereby agree that the Series D Warrant Exercise Price shall be reduced to the Revised Series D Warrant
Exercise Price and the Holder shall fully exercise the Series D Warrant for the number of Series D Warrant Shares underlying such
Holder’s Series D Warrant at the Revised Series D Warrant Exercise Price per share, for aggregate cash proceeds to the Company
in the amount set forth on the Holder’s signature page hereto, pursuant to the terms of the Series D Warrant. Holder shall
execute and deliver the aggregate cash exercise price for such Series D Warrant to the bank account set forth on the Company’s
signature page hereto and the Company shall deliver the Series D Warrant Shares to the Holder via the Depository Trust Company
Deposit or Withdrawal at Custodian system pursuant to the instructions set forth on the Holder’s signature page hereto.

 

    1

     

    

 

Section 2.2 Exercise of Series
E Warrant. Subject to the satisfaction (or waiver) of the closing conditions set forth in Article IV hereof, upon the Closing,
the Company and the Holder hereby agree that the Series E Warrant Exercise Price shall be reduced to the Revised Series E Warrant
Exercise Price and the Holder shall fully exercise the Series E Warrant for the number of Series E Warrant Shares underlying such
Holder’s Series E Warrant at the Revised Series E Warrant Exercise Price per share, for aggregate cash proceeds to the Company
in the amount set forth on the Holder’s signature page hereto, pursuant to the terms of the Series E Warrant. Holder shall
execute and deliver the aggregate cash exercise price for such Series E Warrant to the bank account set forth on the Company’s
signature page hereto and the Company shall deliver the Series E Warrant Shares to the Holder via the Depository Trust Company
Deposit or Withdrawal at Custodian system pursuant to the instructions set forth on the Holder’s signature page hereto.

 

Section 2.3 Exercise of Series
F Warrant. Subject to the satisfaction (or waiver) of the closing conditions set forth in Article IV hereof, upon the Closing,
the Company and the Holder hereby agree that the Series F Warrant Exercise Price shall be reduced to the Revised Series F Warrant
Exercise Price and the Holder shall fully exercise the Series F Warrant for the number of Series F Warrant Shares underlying such
Holder’s Series F Warrant at the Revised Series F Warrant Exercise Price per share, for aggregate cash proceeds to the Company
in the amount set forth on the Holder’s signature page hereto, pursuant to the terms of the Series F Warrant. Holder shall
execute and deliver the aggregate cash exercise price for such Series F Warrant to the bank account set forth on the Company’s
signature page hereto and the Company shall deliver the Series F Warrant Shares to the Holder via the Depository Trust Company
Deposit or Withdrawal at Custodian system pursuant to the instructions set forth on the Holder’s signature page hereto.

 

Section 2.4 Closing. Upon the terms
and subject to the conditions set forth herein, the closing of this Agreement and the exercise of the Series D Warrant (as amended
hereby), Series E Warrant (as amended hereby), and Series F Warrant (as amended hereby) (collectively, the “Warrants”)
contemplated in this Section 2 (the “Closing”) will take place at 2:00 p.m., New York time, on the first
business day after the satisfaction or waiver of the closing conditions set forth in Article IV at Closing, at the offices of Shumaker,
Loop & Kendrick, LLP, 101 E. Kennedy Blvd., Suite 2800, Tampa, Florida, unless another time, date or place is agreed to in
writing by the parties. The date on which the Closing occurs is referred to herein as the “Closing Date.” Upon
Closing, all Warrants exercised pursuant to this Agreement, shall be deemed automatically and immediately cancelled and retired
and shall not be reissued, sold or transferred. Within five (5) business days following the Closing Date, the Holder shall deliver
to the Company the original Series D Warrant, Series E Warrant and Series F Warrant held by Holder (or an affidavit of lost security
with respect to any such Warrant).

 

Section 2.5 Filing of Form 8-K
and Prospectus Supplement. On or before 9:00 a.m., New York time, on the first (1st) Business Day following the Closing, the
Company shall file a Current Report on Form 8-K, including the form of this Agreement (the “8-K Filing”), with
the Securities and Exchange Commission (“Commission”) in the form required by the Securities Exchange Act of
1934, as amended (the “Exchange Act”). From and after the 8-K Filing, the Company represents to the Holder that
it shall have publicly disclosed all material, non-public information delivered to the Holder by the Company, or any of their respective
officers, directors, employees or agents. In addition, effective upon the 8-K Filing, the Company acknowledges and agrees that
any and all confidentiality or similar obligations under any agreement, whether written or oral, between the Company or any of
their respective officers, directors, agents, employees or affiliates on the one hand, and the Holder or any of its affiliates
on the other hand, shall terminate.

 

ARTICLE III

REPRESENTATIONS AND WARRANTIES

 

Section 3.1 Representations
and Warranties of the Company. The Company hereby makes the representations and warranties set forth below to the Holder that
as of the date of its execution of this Agreement and as of the Closing Date:

 

(a) Organization.
The Company is a duly organized and validly existing corporation in good standing under the laws of the State of Nevada.

 

    2

     

    

 

(b) Authorization; Enforcement. The
Company has the requisite corporate power and authority to enter into and to consummate the transactions contemplated by this Agreement
and otherwise to carry out its obligations hereunder and thereunder. The execution and delivery of this Agreement by the Company
and the consummation by it of the transactions contemplated hereby have been duly authorized by all necessary action on the part
of such Company and no further action is required by such Company, its board of directors or its stockholders in connection therewith.
This Agreement has been duly executed by the Company and, when delivered in accordance with the terms hereof will constitute the
valid and binding obligation of the Company enforceable against the Company in accordance with its terms except (i) as limited
by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application
affecting enforcement of creditors’ rights generally, (ii) as limited by laws relating to the availability of specific
performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions
may be limited by applicable law.

 

(c) No Conflicts.
The execution, delivery and performance of this Agreement by the Company and the consummation by the Company of the transactions
contemplated hereby do not and will not: (i) conflict with or violate any provision of the Company’s certificate or
articles of incorporation, bylaws or other organizational or charter documents, or (ii) conflict with, or constitute a default
(or an event that with notice or lapse of time or both would become a default) under, result in the creation of any lien upon any
of the properties or assets of the Company, or give to others any rights of termination, amendment, acceleration or cancellation
(with or without notice, lapse of time or both) of, any agreement, credit facility, debt or other instrument (evidencing Company
debt or otherwise) or other understanding to which the Company is a party or by which any property or asset of the Company is bound
or affected, or (iii) conflict with or result in a violation of any law, rule, regulation, order, judgment, injunction, decree
or other restriction of any court or governmental authority to which the Company is subject (including federal and state securities
laws and regulations), or by which any property or asset of the Company is bound or affected.

 

(d) Issuance of Series
D and E Warrant Shares; Registration Statements. The Series D Warrant Shares, Series E Warrant Shares and Series F Warrant
Shares (collectively, the “Warrant Shares”) are duly authorized and, when issued and paid for in accordance
with the respective terms of the Warrants, will be duly and validly issued, fully paid and nonassessable, free and clear of all
liens imposed by the Company. The Company has prepared and filed registration statements on Form S-1, File No. 333-205757 and Form
S-3, File No. 333-215258 (collectively, the “Registration Statements”) in conformity with the requirements
of the Securities Act of 1933, as amended (the “Securities Act”), which became effective on August 7, 2015
and January 18, 2017 respectively and the combined prospectus for all of the foregoing Registration Statements File No. 333-220538,
which became effective on December 29, 2017 (“Prospectus”), and such amendments and supplements thereto as may
have been required to the date of this Agreement. The 8-K Filing shall be incorporated by reference into the Registration Statements,
thereby updating the Prospectus included therein. The Warrant Shares are registered for issuance or resale, as the case may be,
by the Holder on the Registration Statements and the Company knows of no reasons why such Registration Statements shall not remain
available for the issuance or resale, as the case may be, of such Warrant Shares for the foreseeable future. The Company shall
use its reasonable best efforts to keep the Registration Statements effective and available for use by the Holder until all Warrant
Shares are sold by the Holder. The Registration Statements are effective under the Securities Act and no stop order preventing
or suspending the effectiveness of the Registration Statements or suspending or preventing the use of the Prospectus has been issued
by the Commission and no proceedings for that purpose have been instituted or, to the knowledge of the Company, are threatened
by the Securities and Exchange Commission (“Commission”). At the time the Registration Statements and any amendments
thereto became effective and at the date of this Agreement, the Registration Statements and any amendments thereto conformed and
will conform in all material respects to the requirements of the Securities Act and did not and will not contain any untrue statement
of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein
not misleading; and the Prospectus and any amendments or supplements thereto, at time the Prospectus or any amendment or supplement
thereto was issued and, as of the date hereof, conform in all material respects to the requirements of the Securities Act and did
not and will not contain an untrue statement of a material fact or omit to state a material fact necessary in order to make the
statements therein, in light of the circumstances under which they were made, not misleading.

 

    3

     

    

 

(e) Disclosure. All of
the disclosure furnished by or on behalf of the Company to the Holder regarding the Company and its subsidiaries, their respective
businesses and the transactions contemplated hereby, including but not limited to the disclosure set forth in the SEC Reports,
is true and correct and does not contain any untrue statement of a material fact or omit to state any material fact necessary in
order to make the statements made therein, in light of the circumstances under which they were made, not misleading. As used herein,
“SEC Reports” means all reports, schedules, forms, statements and other documents required to be filed by the
Company with the Commission pursuant to the reporting requirements of the 1934 Act, including all exhibits included therein and
financial statements, notes and schedules thereto and documents incorporated by reference therein.

 

Section 3.2 Representations
and Warranties of the Holder. The Holder hereby makes the representations and warranties set forth below to the Company
that as of the date of its execution of this Agreement and as of the Closing Date:

 

(a) Due Authorization.
The Holder represents and warrants that (i) the execution and delivery of this Agreement by it and the consummation by it
of the transactions contemplated hereby have been duly authorized by all necessary action on its behalf and (ii) this Agreement
has been duly executed and delivered by the Holder and constitutes the valid and binding obligation of the Holder, enforceable
against it in accordance with its terms. 

 

(b) No Conflicts.
The execution, delivery and performance of this Agreement by the Holder and the consummation by the Holder of the transactions
contemplated hereby do not and will not: (i) conflict with or violate any provision of the Holder’s organizational or
charter documents, or (ii) conflict with or result in a violation of any agreement, law, rule, regulation, order, judgment,
injunction, decree or other restriction of any court or governmental authority which would interfere with the ability of the Holder
to perform its obligations under this Agreement.

 

(c) Access to Information.
Such Holder acknowledges that it has had the opportunity to review the reports filed by the Company with the Commission and has
been afforded (i) the opportunity to ask such questions as it has deemed necessary of, and to receive answers from, representatives
of the Company concerning the terms and conditions of the exercise of the Warrants and the merits and risks of investing in the
Warrant Shares; (ii) access to information about the Company and its financial condition, results of operations, business,
properties, management and prospects sufficient to enable it to evaluate its investment; and (iii) the opportunity to obtain
such additional information that the Company possesses or can acquire without unreasonable effort or expense that is necessary
to make an informed investment decision with respect to the investment. 

 

(d) Holder Status.
The Holder is an “accredited investor” as defined in Rule 501 under the Securities Act.

 

(e) Understandings or
Arrangements. Such Holder is acquiring the Warrant Shares as principal for its own account and has no direct or indirect arrangement
or understandings with any other persons to distribute or regarding the distribution of such Warrant Shares (this representation
and warranty not limiting such Holder’s right to sell the Warrant Shares pursuant to the Registration Statements or otherwise
in compliance with applicable federal and state securities laws). Such Holder is acquiring the Warrant Shares hereunder in the
ordinary course of its business.

 

(f) The Holder has good and
transferable title to, and is the sole owner of the Warrants, and all of such Warrants are free and clear of liens, claims or encumbrances
of any kind.

 

(g) Compliance with Limitations
on Exercises. The Holder represents and warrants that as of the Closing, the exercise of the Warrants at the Closing does not
violate the limitations on exercises set forth in Section 1(f) of each Warrant.

 

    4

     

    

 

ARTICLE IV

CLOSING CONDITIONS

 

Section 4.1 Holder’s Closing
Conditions. The Holder’s obligations to consummate the transactions contemplated hereby are subject to satisfaction or
waiver, in the discretion of the Holder, of the following conditions:

 

(a) the Company shall have executed
and delivered to the Holder this Agreement;

 

(b) a copy of the irrevocable instructions
to the Transfer Agent instructing the Transfer Agent to deliver, on an expedited basis, the Warrant Shares to the Holder via the
Depository Trust Company Deposit or Withdrawal at Custodian system; and

 

(c) the accuracy in all material
respects (or to the extent representations or warranties are qualified by materiality or material adverse effect, in all respects)
when made and on the Closing Date of the representations and warranties of the Company contained herein (unless as of a specific
date therein, in which case they shall be true and correct as of such date).

 

(d) the Registration Statements
shall remain effective and available for the issuance or resale, as the case may be, of the Warrant Shares.

 

Section 4.2 Company Closing Conditions.  The
Company’s obligation to consummate the transactions contemplated hereby are subject to satisfaction or waiver, in the discretion
of the Company, of the following conditions:

 

(a) 
the Holder shall have executed and delivered to the Company this Agreement;

  

(b) the accuracy in all material
respects (or to the extent representations or warranties are qualified by materiality or material adverse effect, in all respects)
when made and on the Closing Date of the representations and warranties of the Holder contained herein (unless as of a specific
date therein, in which case they shall be true and correct as of such date); and

  

(c) 
the Holder shall have executed a Voting and Support Agreement in the form attached hereto as Exhibit A with regard
to the Company’s anticipated reverse triangular merger with Marker Therapeutics, Inc.

 

ARTICLE V

MISCELLANEOUS

 

Section 5.1 [Reserved]

 

Section 5.2 Other Holders. The Company
acknowledges and agrees that the obligations of the Holder under this Agreement are several and not joint with the obligations
of any other holder or any other holders of the Series A Warrants, Series A-1 Warrants, Series C Warrants, Series D Warrants, Series
D-1 Warrants, Series E Warrants, Series E-1 Warrants, Series F Warrants and Series F-1 Warrants of the Company (each, an “Other
Holder”) under any other agreement related to the exercise of such warrants (“Other Warrant Exercise Agreement”),
and the Holder shall not be responsible in any way for the performance of the obligations of any Other Holder or under any such
Other Warrant Exercise Agreement. Nothing contained in this Agreement, and no action taken by the Holder pursuant hereto, shall
be deemed to constitute the Holder and the Other Holders as a partnership, an association, a joint venture or any other kind of
entity, or create a presumption that the Holder and the Other Holders are in any way acting in concert or as a group with respect
to such obligations or the transactions contemplated by this Agreement and the Company acknowledges that the Holder and the Other
Holders are not acting in concert or as a group with respect to such obligations or the transactions contemplated by this Agreement
or any Other Warrant Exercise Agreement. The Company and the Holder confirm that the Holder has independently participated in the
negotiation of the transactions contemplated hereby with the advice of its own counsel and advisors. The Holder shall be entitled
to independently protect and enforce their rights, including, without limitation, the rights arising out of this Agreement, and
it shall not be necessary for any Other Holder to be joined as an additional party in any proceeding for such purpose. The Company
hereby represents and warrants as of the date hereof and covenants and agrees from and after the date hereof that none of the terms
offered to any Other Holder with respect to any Other Warrant Exercise Agreement (or any amendment, modification or waiver thereof)
(each an "Amendment Document"), is or will be more favorable to such Other Holder than those of the Holder pursuant
to this Agreement. If prior to Closing, the Company enters into an Amendment Document, then (i) the Company shall provide notice
thereof to the Holder immediately following the occurrence thereof and (ii) the terms and conditions of this Agreement shall be,
without any further action by the Holder or the Company, automatically amended and modified in an economically and legally equivalent
manner such that the Holder shall receive the benefit of the more favorable terms and/or conditions (as the case may be) set forth
in such Amendment Document, provided that upon written notice to the Company at any time the Holder may elect not to accept the
benefit of any such amended or modified term or condition, in which event the term or condition contained in this Agreement shall
apply to the Holder as it was in effect immediately prior to such amendment or modification as if such amendment or modification
never occurred with respect to the Holder. The provisions of this Section 5.2 shall apply similarly and equally to each Amendment
Document.

 

    5

     

    

 

Section 5.3 Notices. Any
and all notices or other communications or deliveries required or permitted to be provided hereunder shall be made in accordance
with Section 8 of the Warrants.

 

Section 5.4 Survival.
All representations and warranties (as of the date such representations and warranties were made) made herein or in any certificate
or other instrument delivered by it or on its behalf under this Agreement shall be considered to have been relied upon by the parties
hereto and shall survive the issuance of the Warrant Shares. This Agreement shall inure to the benefit of and be binding upon the
successors and permitted assigns of each of the parties; provided however that no party may assign this Agreement or the obligations
and rights of such party hereunder without the prior written consent of the other parties hereto.

 

Section 5.5 Execution.
This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same
agreement and shall become effective when counterparts have been signed by each party and delivered to the other party, it being
understood that both parties need not sign the same counterpart. In the event that any signature is delivered by facsimile transmission,
such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed)
with the same force and effect as if such facsimile signature page were an original thereof.

 

Section 5.6 Severability.
If any provision of this Agreement is held to be invalid or unenforceable in any respect, the validity and enforceability of the
remaining terms and provisions of this Agreement shall not in any way be affected or impaired thereby and the parties will attempt
to agree upon a valid and enforceable provision that is a reasonable substitute therefor, and upon so agreeing, shall incorporate
such substitute provision in this Agreement.

 

Section 5.7 Governing Law.
All questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be determined pursuant
to Section 11 of the Warrants.

 

Section 5.8 Entire Agreement.
The Agreement, together with the exhibits and schedules thereto, contain the entire understanding of the parties with respect to
the subject matter hereof and supersede all prior agreements and understandings, oral or written, with respect to such matters,
which the parties acknowledge have been merged into such documents, exhibits and schedules.

 

Section 5.9 Construction.
The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to limit or affect
any of the provisions hereof. The language used in this Agreement will be deemed to be the language chosen by the parties to express
their mutual intent, and no rules of strict construction will be applied against any party.

 

Section 5.10 Effectiveness. This
Agreement shall be effective only upon the Company returning a fully-executed copy of this Agreement to the Holder.

 

[Signature Pages
to Follow]

 

    6

     

    

 

IN WITNESS WHEREOF, the parties hereto
have caused this Agreement to be duly executed by their respective authorized signatories as of the date first indicated above.

 

	 	TAPIMMUNE INC.
	 	
         

         
	 
	 	By: 	/s/Peter Hoang
	 	 	
        Name: Peter Hoang

        Title: President and Chief Executive Officer

 

Wire Instructions:

 

DOMESTIC WIRE

 

	ABA	 
	Bank Name	 
	Bank Address	 
	Beneficiary Account Number (BNF)	 
	Beneficiary Account Name	 

 

FOREIGN WIRE

 

	ABA	 
	Bank Name	 
	Bank Address	 
	Beneficiary Account Number (BNF)	 
	Beneficiary Account Name	 
	SWIFT Code	 

 

    [Signature Page to Warrant Exercise Agreement (Empery)]

     

    

  

[HOLDER SIGNATURE PAGE TO

WARRANT EXERCISE AGREEMENT]

 

IN WITNESS WHEREOF, the undersigned have
caused this Agreement to be duly executed by their respective authorized signatories as of the date first indicated above.

 

Name of Holder: Empery Asset Master, Ltd

 

Signature of Authorized Signatory of Holder: /s/Brett
Director

 

Name of Authorized Signatory: Brett Director

 

Title of Authorized Signatory: General Counsel of Empery Asset
Management, Authorized Agent of the Holder

 

Date: May 14, 2018

 

Total Number of Series D Warrant Shares Underlying Series D
Warrant: 59,555

Revised Series D Warrant Exercise Price: $2.50

Aggregate Exercise Price to be Paid: $148,887.50

Number of Series D Warrant Shares to be Issued Upon Exercise: 59,555

 

Total Number of Series E Warrant Shares Underlying Series E
Warrant: 59,555

Revised Series E Warrant Exercise Price: $2.50

Aggregate Exercise Price to be Paid: $148,887.50

Number of Series E Warrant Shares to be Issued Upon Exercise: 59,555

 

Total Number of Series F Warrant Shares Underlying Series F
Warrant: 59,555

Revised Series F Warrant Exercise Price: $2.50

Aggregate Exercise Price to be Paid: $148,887.50

Number of Series F Warrant Shares to be Issued Upon Exercise: 59,555

 

 

 DWAC Instructions for Warrant Shares:

 

An aggregate of 178,665 Warrant Shares to be delivered to the
following account:

DTC:

Account Name:

Account #:

 

    [Signature Page to Warrant Exercise Agreement (Empery)]

     

    

 

[HOLDER SIGNATURE PAGE TO

WARRANT EXERCISE AGREEMENT]

 

IN WITNESS WHEREOF, the undersigned have
caused this Agreement to be duly executed by their respective authorized signatories as of the date first indicated above.

 

Name of Holder: Empery Tax Efficient, LP

 

Signature of Authorized Signatory of Holder: /s/Brett
Director

 

Name of Authorized Signatory: Brett Director

 

Title of Authorized Signatory: General Counsel of Empery Asset
Management, Authorized Agent of the Holder

 

Date: May 14, 2018

 

Total Number of Series D Warrant Shares Underlying Series D
Warrant: 14,241

Revised Series D Warrant Exercise Price: $2.50

Aggregate Exercise Price to be Paid: $35,602.50

Number of Series D Warrant Shares to be Issued Upon Exercise: 14,241

 

Total Number of Series E Warrant Shares Underlying Series E
Warrant: 14,241

Revised Series E Warrant Exercise Price: $2.50

Aggregate Exercise Price to be Paid: $35,602.50

Number of Series E Warrant Shares to be Issued Upon Exercise: 14,241

 

Total Number of Series F Warrant Shares Underlying Series F
Warrant: 14,241

Revised Series F Warrant Exercise Price: $2.50

Aggregate Exercise Price to be Paid: $35,602.50

Number of Series F Warrant Shares to be Issued Upon Exercise: 14,241

 

 

DWAC Instructions for Warrant Shares:

 

An aggregate of 12,174 Warrant Shares to be delivered to the
following account:

DTC:

Account Name:

Account #:

 

An aggregate of 30,549 Warrant Shares to be delivered to the
following account:

DTC:

Account Name:

Account #:

 

    [Signature Page to Warrant Exercise Agreement (Empery)]

     

    

 

[HOLDER SIGNATURE PAGE TO

WARRANT EXERCISE AGREEMENT]

 

IN WITNESS WHEREOF, the undersigned have
caused this Agreement to be duly executed by their respective authorized signatories as of the date first indicated above.

 

Name of Holder: Empery Tax Efficient II, LP

 

Signature of Authorized Signatory of Holder: /s/Brett
Director

 

Name of Authorized Signatory: Brett Director

 

Title of Authorized Signatory: General Counsel of Empery Asset
Management, Authorized Agent of the Holder

 

Date: May 14, 2018

 

Total Number of Series D Warrant Shares Underlying Series D Warrant: 119,538

Revised Series D Warrant Exercise Price: $2.50

Aggregate Exercise Price to be Paid: $298,845.00

Number of Series D Warrant Shares to be Issued Upon Exercise: 119,538

 

Total Number of Series E Warrant Shares Underlying Series E
Warrant: 119,538

Revised Series E Warrant Exercise Price: $2.50

Aggregate Exercise Price to be Paid: $298,845.00

Number of Series E Warrant Shares to be Issued Upon Exercise: 119,538

 

Total Number of Series F Warrant Shares Underlying Series F
Warrant: 119,538

Revised Series F Warrant Exercise Price: $2.50

Aggregate Exercise Price to be Paid: $298,845.00

Number of Series F Warrant Shares to be Issued Upon Exercise: 119,538

 

 

DWAC Instructions for Warrant Shares:

 

An aggregate of 358,614 Warrant Shares to be delivered to the
following account:

DTC:

Account Name:

Account #:

 

    [Signature Page to Warrant Exercise Agreement (Empery)]Exhibit 10.3

 

WARRANT EXERCISE AGREEMENT

 

This Warrant Exercise Agreement (this “Agreement”),
dated as of May 14, 2018, is by and between TapImmune Inc., a Nevada corporation (the “Company”) and Brio Capital
Master Fund Ltd. (the “Holder”) of those certain (i) Series C Warrant to Purchase Common Stock issued by the
Company to the Holder, a portion of which warrant is exercisable at an exercise price (the “Series C Warrant Exercise
Price”) of $6.00 per share (the “Series C Warrant”); (ii) Series D Warrant to Purchase Common Stock
issued by the Company to the Holder, a portion of which warrant is exercisable at an exercise price (the “Series D Warrant
Exercise Price”) of $9.00 per share (the “Series D Warrant”); (iii) Series E Warrant to Purchase Common
Stock issued by the Company to the Holder, a portion of which warrant is exercisable at an exercise price (the “Series
E Warrant Exercise Price”) of $15.00 per share (the “Series E Warrant”); and (iv) Series F Warrant
to Purchase Common Stock issued by the Company to the Holder, a portion of which warrant is exercisable at an exercise price (the
“Series F Warrant Exercise Price”) of $7.20 per share (the “Series F Warrant”).

 

WHERAS, the Holder’s Series C Warrant,
Series D Warrant , Series E Warrant and Series F Warrant are exercisable for a number of shares of common stock, par value $0.001
per share, of the Company (the “Common Stock”) as set forth on such Holder’s signature page hereto;

 

WHERAS, the Holder desires to partially
exercise such Series C Warrant with respect to 49,583 shares of Common Stock (the “Series C Warrant Shares”)
and, immediately prior to such exercise and in consideration of the Holder’s agreement to so exercise such Series C Warrant,
the Company has agreed to reduce the Series C Warrant Exercise Price for such exercised portion of the Series C Warrant to $2.50
per share (the “Revised Series C Warrant Exercise Price”) resulting in an aggregate exercise price of approximately
$123,957.50 as set forth on the Holder’s signature page hereto;

 

WHERAS, the Holder desires to partially
exercise such Series D Warrant with respect to 52,083 shares of Common Stock (the “Series D Warrant Shares”)
and, immediately prior to such exercise and in consideration of the Holder’s agreement to so exercise such Series D Warrant,
the Company has agreed to reduce the Series D Warrant Exercise Price for such exercised portion of the Series D Warrant to $2.50
per share (the “Revised Series D Warrant Exercise Price”) resulting in an aggregate exercise price of approximately
$130,207.50 as set forth on the Holder’s signature page hereto;

 

WHERAS, the Holder desires to partially
exercise such Series E Warrant with respect to 31,091 shares of Common Stock (the “Series E Warrant Shares”)
and, immediately prior to such exercise and in consideration of the Holder’s agreement to so exercise such Series E Warrant,
the Company has agreed to reduce the Series E Warrant Exercise Price for such exercised portion of the Series E Warrant to $2.50
per share (the “Revised Series E Warrant Exercise Price”) resulting in an aggregate exercise price of approximately
$77,727.50 as set forth on the Holder’s signature page hereto; and

 

WHERAS, the Holder desires to partially
exercise such Series F Warrant with respect to 48,333 shares of Common Stock (the “Series F Warrant Shares”)
and, immediately prior to such exercise and in consideration of the Holder’s agreement to so exercise such Series F Warrant,
the Company has agreed to reduce the Series F Warrant Exercise Price for such exercised portion of the Series C Warrant to $2.50
per share (the “Revised Series F Warrant Exercise Price”) resulting in an aggregate exercise price of approximately
$120,832.50 as set forth on the Holder’s signature page hereto.

 

NOW, THEREFORE, IN CONSIDERATION of the
mutual covenants contained in this Agreement, and for good and valuable consideration the receipt and adequacy of which are hereby
acknowledged, the Holder and the Company agree as follows:

 

ARTICLE I

DEFINITIONS

 

Section 1.1 Definitions.
Capitalized terms not defined in this Agreement shall have the respective meanings ascribed to such terms in the Series C Warrant,
Series D Warrant, Series E Warrant and Series F Warrant (collectively, the “Warrants”).

 

    1

     

    

 

ARTICLE II

EXERCISE OF WARRANTS; 

REDUCTION OF EXERCISE PRICES OF WARRANTS;
FIRST CLOSING AND SECOND CLOSING

  

Section 2.1 Exercise of Series
C Warrant. Subject to the satisfaction (or waiver) of the closing conditions set forth in Article IV hereof, upon the Second
Closing, the Company and the Holder hereby agree that the Series C Warrant Exercise Price with respect to the Series C Warrant
Shares shall be reduced to the Revised Series C Warrant Exercise Price and the Holder shall partially exercise the Series C Warrant
for the number of Series C Warrant Shares at the Revised Series C Warrant Exercise Price per share, for aggregate cash proceeds
to the Company in the amount set forth on the Holder’s signature page hereto, pursuant to the terms of the Series C Warrant.
Holder shall execute and deliver the aggregate cash exercise price for such Series C Warrant to the bank account set forth on the
Company’s signature page hereto and the Company shall deliver the Series C Warrant Shares to the Holder via the Depository
Trust Company Deposit or Withdrawal at Custodian system pursuant to the instructions set forth on the Holder’s signature
page hereto.

 

Section 2.2 Exercise of Series
D Warrant. Subject to the satisfaction (or waiver) of the closing conditions set forth in Article IV hereof, upon the First
Closing, the Company and the Holder hereby agree that the Series D Warrant Exercise Price with respect to the Series D Warrant
Shares shall be reduced to the Revised Series D Warrant Exercise Price and the Holder shall partially exercise the Series D Warrant
for the number of Series D Warrant Shares at the Revised Series D Warrant Exercise Price per share, for aggregate cash proceeds
to the Company in the amount set forth on the Holder’s signature page hereto, pursuant to the terms of the Series D Warrant.
Holder shall execute and deliver the aggregate cash exercise price for such Series D Warrant to the bank account set forth on the
Company’s signature page hereto and the Company shall deliver the Series D Warrant Shares to the Holder via the Depository
Trust Company Deposit or Withdrawal at Custodian system pursuant to the instructions set forth on the Holder’s signature
page hereto.

 

Section 2.3 Exercise of Series
E Warrant. Subject to the satisfaction (or waiver) of the closing conditions set forth in Article IV hereof, upon the First
Closing, the Company and the Holder hereby agree that the Series E Warrant Exercise Price with respect to the Series E Warrant
Shares shall be reduced to the Revised Series E Warrant Exercise Price and the Holder shall partially exercise the Series E Warrant
for the number of Series E Warrant Shares at the Revised Series E Warrant Exercise Price per share, for aggregate cash proceeds
to the Company in the amount set forth on the Holder’s signature page hereto, pursuant to the terms of the Series E Warrant.
Holder shall execute and deliver the aggregate cash exercise price for such Series E Warrant to the bank account set forth on the
Company’s signature page hereto and the Company shall deliver the Series E Warrant Shares to the Holder via the Depository
Trust Company Deposit or Withdrawal at Custodian system pursuant to the instructions set forth on the Holder’s signature
page hereto.

 

Section 2.4 Exercise of Series
F Warrant. Subject to the satisfaction (or waiver) of the closing conditions set forth in Article IV hereof, upon the Second
Closing, the Company and the Holder hereby agree that the Series F Warrant Exercise Price with respect to the Series E Warrant
Shares shall be reduced to the Revised Series F Warrant Exercise Price and the Holder shall partially exercise the Series F Warrant
for the number of Series F Warrant Shares at the Revised Series F Warrant Exercise Price per share, for aggregate cash proceeds
to the Company in the amount set forth on the Holder’s signature page hereto, pursuant to the terms of the Series F Warrant.
Holder shall execute and deliver the aggregate cash exercise price for such Series F Warrant to the bank account set forth on the
Company’s signature page hereto and the Company shall deliver the Series F Warrant Shares to the Holder via the Depository
Trust Company Deposit or Withdrawal at Custodian system pursuant to the instructions set forth on the Holder’s signature
page hereto.

 

Section 2.5 Closing. Upon the terms
and subject to the conditions set forth herein, (i) the closing of the partial exercise of the Series D Warrant (as amended hereby)
and Series E Warrant (as amended hereby) contemplated in this Section 2 (“the “First Closing”) will take
place at 10:00 a.m., New York time, on the first business day after the satisfaction or waiver of the closing conditions set
forth in Article IV at the First Closing and (ii) the closing of the partial exercise of the Series C Warrant (as amended hereby)
and Series F Warrant (as amended hereby) contemplated in this Section 2 (“the “Second Closing”) will take
place at 2:00 p.m., New York time, on the first business day after the satisfaction or waiver of the closing conditions set
forth in Article IV at the Second Closing, at the offices of Shumaker, Loop & Kendrick, LLP, 101 E. Kennedy Blvd., Suite 2800,
Tampa, Florida, unless another time, date or place is agreed to in writing by the parties. The date on which the First Closing
and Second Closing occurs is referred to herein as the “Closing Date.” Upon the First Closing and Second Closing,
all Warrants exercised pursuant to this Agreement, shall be deemed automatically and immediately cancelled and retired and shall
not be reissued, sold or transferred. Within five (5) business days following the Closing Date, the Holder shall deliver to the
Company the original Series C Warrant, Series D Warrant, Series E Warrant and Series F Warrant held by Holder and the Company will
issue a replacement Series C Warrant, Series D Warrant, Series E Warrant and Series F Warrant exercisable for a number of shares
of Common Stock and at an exercise price as set forth on such Holder’s signature page hereto pursuant to that certain Warrant
Exercise Agreement dated June 21, 2017 between the Company and the Holder promptly after the Holder’s delivery of the original
Warrants.

 

    2

     

    

 

Section 2.6 Filing of Form 8-K
and Prospectus Supplement. On or before 9:00 a.m., New York time, on the first (1st) Business Day following the Closing Date,
the Company shall file a Current Report on Form 8-K, including the form of this Agreement (the “8-K Filing”),
with the Securities and Exchange Commission (“Commission”) in the form required by the Securities Exchange Act
of 1934, as amended (the “Exchange Act”). From and after the 8-K Filing, the Company represents to the Holder
that it shall have publicly disclosed all material, non-public information delivered to the Holder by the Company, or any of their
respective officers, directors, employees or agents. In addition, effective upon the 8-K Filing, the Company acknowledges and agrees
that any and all confidentiality or similar obligations under any agreement, whether written or oral, between the Company or any
of their respective officers, directors, agents, employees or affiliates on the one hand, and the Holder or any of its affiliates
on the other hand, shall terminate.

 

ARTICLE III

REPRESENTATIONS AND WARRANTIES

 

Section 3.1 Representations
and Warranties of the Company. The Company hereby makes the representations and warranties set forth below to the Holder that
as of the date of its execution of this Agreement and as of the Closing Date:

 

(a) Organization.
The Company is a duly organized and validly existing corporation in good standing under the laws of the State of Nevada.

 

(b) Authorization; Enforcement. The
Company has the requisite corporate power and authority to enter into and to consummate the transactions contemplated by this Agreement
and otherwise to carry out its obligations hereunder and thereunder. The execution and delivery of this Agreement by the Company
and the consummation by it of the transactions contemplated hereby have been duly authorized by all necessary action on the part
of such Company and no further action is required by such Company, its board of directors or its stockholders in connection therewith.
This Agreement has been duly executed by the Company and, when delivered in accordance with the terms hereof will constitute the
valid and binding obligation of the Company enforceable against the Company in accordance with its terms except (i) as limited
by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application
affecting enforcement of creditors’ rights generally, (ii) as limited by laws relating to the availability of specific
performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions
may be limited by applicable law.

 

(c) No Conflicts.
The execution, delivery and performance of this Agreement by the Company and the consummation by the Company of the transactions
contemplated hereby do not and will not: (i) conflict with or violate any provision of the Company’s certificate or
articles of incorporation, bylaws or other organizational or charter documents, or (ii) conflict with, or constitute a default
(or an event that with notice or lapse of time or both would become a default) under, result in the creation of any lien upon any
of the properties or assets of the Company, or give to others any rights of termination, amendment, acceleration or cancellation
(with or without notice, lapse of time or both) of, any agreement, credit facility, debt or other instrument (evidencing Company
debt or otherwise) or other understanding to which the Company is a party or by which any property or asset of the Company is bound
or affected, or (iii) conflict with or result in a violation of any law, rule, regulation, order, judgment, injunction, decree
or other restriction of any court or governmental authority to which the Company is subject (including federal and state securities
laws and regulations), or by which any property or asset of the Company is bound or affected.

 

    3

     

    

 

(d) Issuance of Series
C, D, E and F Warrant Shares; Registration Statements. The Series C Warrant Shares, Series D Warrant Shares, Series E Warrant
Shares and Series F Warrant Shares (collectively, the “Warrant Shares”) are duly authorized and, when issued
and paid for in accordance with the respective terms of the Warrants, will be duly and validly issued, fully paid and nonassessable,
free and clear of all liens imposed by the Company. The Company has prepared and filed registration statements on Form S-1, File
No. 333-205757 and Form S-3, File No. 333-215258 (collectively, the “Registration Statements”) in conformity
with the requirements of the Securities Act of 1933, as amended (the “Securities Act”), which became effective
on August 7, 2015 and January 18, 2017 respectively and the combined prospectus for all of the foregoing Registration Statements
File No. 333-220538, which became effective on December 29, 2017 (“Prospectus”), and such amendments and supplements
thereto as may have been required to the date of this Agreement. The 8-K Filing shall be incorporated by reference into the Registration
Statements, thereby updating the Prospectus included therein. The Warrant Shares are registered for issuance and/or resale, as
applicable, by the Holder on the Registration Statements and the Company knows of no reasons why such Registration Statements shall
not remain available for the issuance and/or resale, as applicable, of such Warrant Shares for the foreseeable future. The Company
shall use its reasonable best efforts to keep the Registration Statements effective and available for use by the Holder until all
Warrant Shares are sold by the Holder. The Registration Statements are effective under the Securities Act and no stop order preventing
or suspending the effectiveness of the Registration Statements or suspending or preventing the use of the Prospectus has been issued
by the Commission and no proceedings for that purpose have been instituted or, to the knowledge of the Company, are threatened
by the Securities and Exchange Commission (“Commission”). At the time the Registration Statements and any amendments
thereto became effective and at the date of this Agreement, the Registration Statements and any amendments thereto conformed and
will conform in all material respects to the requirements of the Securities Act and did not and will not contain any untrue statement
of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein
not misleading; and the Prospectus and any amendments or supplements thereto, at time the Prospectus or any amendment or supplement
thereto was issued and, as of the date hereof, conform in all material respects to the requirements of the Securities Act and did
not and will not contain an untrue statement of a material fact or omit to state a material fact necessary in order to make the
statements therein, in light of the circumstances under which they were made, not misleading.

 

(e) Disclosure. All of
the disclosure furnished by or on behalf of the Company to the Holder regarding the Company and its subsidiaries, their respective
businesses and the transactions contemplated hereby, including but not limited to the disclosure set forth in the SEC Reports,
is true and correct and does not contain any untrue statement of a material fact or omit to state any material fact necessary in
order to make the statements made therein, in light of the circumstances under which they were made, not misleading. As used herein,
“SEC Reports” means all reports, schedules, forms, statements and other documents required to be filed by the
Company with the Commission pursuant to the reporting requirements of the 1934 Act, including all exhibits included therein and
financial statements, notes and schedules thereto and documents incorporated by reference therein.

 

Section 3.2 Representations
and Warranties of the Holder. The Holder hereby makes the representations and warranties set forth below to the Company
that as of the date of its execution of this Agreement and as of the Closing Date:

 

(a) Due Authorization.
The Holder represents and warrants that (i) the execution and delivery of this Agreement by it and the consummation by it
of the transactions contemplated hereby have been duly authorized by all necessary action on its behalf and (ii) this Agreement
has been duly executed and delivered by the Holder and constitutes the valid and binding obligation of the Holder, enforceable
against it in accordance with its terms. 

 

(b) No Conflicts.
The execution, delivery and performance of this Agreement by the Holder and the consummation by the Holder of the transactions
contemplated hereby do not and will not: (i) conflict with or violate any provision of the Holder’s organizational or
charter documents, or (ii) conflict with or result in a violation of any agreement, law, rule, regulation, order, judgment,
injunction, decree or other restriction of any court or governmental authority which would interfere with the ability of the Holder
to perform its obligations under this Agreement.

 

    4

     

    

 

(c) Access to Information.
Such Holder acknowledges that it has had the opportunity to review the reports filed by the Company with the Commission and has
been afforded (i) the opportunity to ask such questions as it has deemed necessary of, and to receive answers from, representatives
of the Company concerning the terms and conditions of the exercise of the Warrants and the merits and risks of investing in the
Warrant Shares; (ii) access to information about the Company and its financial condition, results of operations, business,
properties, management and prospects sufficient to enable it to evaluate its investment; and (iii) the opportunity to obtain
such additional information that the Company possesses or can acquire without unreasonable effort or expense that is necessary
to make an informed investment decision with respect to the investment. 

 

(d) Holder Status.
The Holder is an “accredited investor” as defined in Rule 501 under the Securities Act.

 

(e) Understandings or
Arrangements. Such Holder is acquiring the Warrant Shares as principal for its own account and has no direct or indirect arrangement
or understandings with any other persons to distribute or regarding the distribution of such Warrant Shares (this representation
and warranty not limiting such Holder’s right to sell the Warrant Shares pursuant to the Registration Statements or otherwise
in compliance with applicable federal and state securities laws). Such Holder is acquiring the Warrant Shares hereunder in the
ordinary course of its business.

 

(f) Title to Warrants.
The Holder has good and transferable title to, and is the sole owner of the Warrants, and all of such Warrants are free and clear
of liens, claims or encumbrances of any kind.

 

(g) Compliance with Limitations
on Exercises. The Holder represents and warrants that as of the First Closing and as of the Second Closing, the portion of
the Warrants exercised at each closing do not violate the limitations on exercises set forth in Section 1(f) of each Warrant.

 

ARTICLE IV

CLOSING CONDITIONS

 

Section 4.1 Holder’s Closing
Conditions. The Holder’s obligations to consummate the transactions contemplated hereby are subject to satisfaction or
waiver, in the discretion of the Holder, of the following conditions:

 

(a) the Company shall have executed
and delivered to the Holder this Agreement;

 

(b) a copy of the irrevocable instructions
to the Transfer Agent instructing the Transfer Agent to deliver, on an expedited basis, the Warrant Shares to the Holder via the
Depository Trust Company Deposit or Withdrawal at Custodian system; and

 

(c) the accuracy in all material
respects (or to the extent representations or warranties are qualified by materiality or material adverse effect, in all respects)
when made and on the Closing Date of the representations and warranties of the Company contained herein (unless as of a specific
date therein, in which case they shall be true and correct as of such date).

 

Section 4.2 Company Closing Conditions.  The
Company’s obligation to consummate the transactions contemplated hereby are subject to satisfaction or waiver, in the discretion
of the Company, of the following conditions:

 

(a) 
the Holder shall have executed and delivered to the Company this Agreement;

 

    5

     

    

 

(b) the accuracy in all material
respects (or to the extent representations or warranties are qualified by materiality or material adverse effect, in all respects)
when made and on the Closing Date of the representations and warranties of the Holder contained herein (unless as of a specific
date therein, in which case they shall be true and correct as of such date); and

  

(c) 
the Holder shall have executed a Voting and Support Agreement with regard to the Company’s anticipated reverse triangular
merger with Marker Therapeutics, Inc.

 

ARTICLE V

MISCELLANEOUS

 

Section 5.1 Short Sales. After
the Closing Date, the Holder covenants that neither it nor any affiliates acting on its behalf or pursuant to any understanding
with it will execute any Short Sales (as defined below) during the period from the date hereof until the one year anniversary of
the date of this Agreement. “Short Sales” means all “short sales” as defined in Rule 200 of Regulation
SHO under the Exchange Act (but shall not be deemed to include the location and/or reservation of borrowable shares of Common Stock).

 

Section 4.3 Other Holders. The Company
acknowledges and agrees that the obligations of the Holder under this Agreement are several and not joint with the obligations
of any other holder or any other holders of the Series A Warrants, Series A-1 Warrants, Series C Warrants, Series D Warrants, Series
D-1 Warrants, Series E Warrants, Series E-1 Warrants, Series F Warrants and Series F-1 Warrants of the Company (each, an “Other
Holder”) under any other agreement related to the exercise of such warrants (“Other Warrant Exercise Agreement”),
and the Holder shall not be responsible in any way for the performance of the obligations of any Other Holder or under any such
Other Warrant Exercise Agreement. Nothing contained in this Agreement, and no action taken by the Holder pursuant hereto, shall
be deemed to constitute the Holder and the Other Holders as a partnership, an association, a joint venture or any other kind of
entity, or create a presumption that the Holder and the Other Holders are in any way acting in concert or as a group with respect
to such obligations or the transactions contemplated by this Agreement and the Company acknowledges that the Holder and the Other
Holders are not acting in concert or as a group with respect to such obligations or the transactions contemplated by this Agreement
or any Other Warrant Exercise Agreement. The Company and the Holder confirm that the Holder has independently participated in the
negotiation of the transactions contemplated hereby with the advice of its own counsel and advisors. The Holder shall be entitled
to independently protect and enforce their rights, including, without limitation, the rights arising out of this Agreement, and
it shall not be necessary for any Other Holder to be joined as an additional party in any proceeding for such purpose. The Company
hereby represents and warrants as of the date hereof and covenants and agrees from and after the date hereof that none of the terms
offered to any Other Holder with respect to any Other Warrant Exercise Agreement (or any amendment, modification or waiver thereof),
is or will be more favorable to such Other Holder than those of the Holder pursuant to this Agreement.

 

Section 5.3 Notices. Any
and all notices or other communications or deliveries required or permitted to be provided hereunder shall be made in accordance
with Section 8 of the Warrants.

 

Section 5.4 Survival.
All representations and warranties (as of the date such representations and warranties were made) made herein or in any certificate
or other instrument delivered by it or on its behalf under this Agreement shall be considered to have been relied upon by the parties
hereto and shall survive the issuance of the Warrant Shares. This Agreement shall inure to the benefit of and be binding upon the
successors and permitted assigns of each of the parties; provided however that no party may assign this Agreement or the obligations
and rights of such party hereunder without the prior written consent of the other parties hereto.

 

Section 5.5 Execution.
This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same
agreement and shall become effective when counterparts have been signed by each party and delivered to the other party, it being
understood that both parties need not sign the same counterpart. In the event that any signature is delivered by facsimile transmission,
such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed)
with the same force and effect as if such facsimile signature page were an original thereof.

 

    6

     

    

 

Section 5.6 Severability.
If any provision of this Agreement is held to be invalid or unenforceable in any respect, the validity and enforceability of the
remaining terms and provisions of this Agreement shall not in any way be affected or impaired thereby and the parties will attempt
to agree upon a valid and enforceable provision that is a reasonable substitute therefor, and upon so agreeing, shall incorporate
such substitute provision in this Agreement.

 

Section 5.7 Governing Law.
All questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be determined pursuant
to Section 11 of the Warrants.

 

Section 5.8 Entire Agreement.
The Agreement, together with the exhibits and schedules thereto, contain the entire understanding of the parties with respect to
the subject matter hereof and supersede all prior agreements and understandings, oral or written, with respect to such matters,
which the parties acknowledge have been merged into such documents, exhibits and schedules.

 

Section 5.9 Construction.
The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to limit or affect
any of the provisions hereof. The language used in this Agreement will be deemed to be the language chosen by the parties to express
their mutual intent, and no rules of strict construction will be applied against any party.

 

Section 5.10 Effectiveness. This
Agreement shall be effective only upon the Company returning a fully-executed copy of this Agreement to the Holder.

 

[Signature Pages
to Follow]

 

    7

     

    

 

IN WITNESS WHEREOF, the parties hereto
have caused this Agreement to be duly executed by their respective authorized signatories as of the date first indicated above.

 

	 	TAPIMMUNE INC.
	 	
         

         
	 
	 	By: 	/s/Peter Hoang
	 	 	
        Name: Peter Hoang

        Title: President and Chief Executive Officer

 

Wire Instructions:

 

DOMESTIC WIRE

 

	ABA	 
	Bank Name	 
	Bank Address	 
	Beneficiary Account Number (BNF)	 
	Beneficiary Account Name	 

 

FOREIGN WIRE

 

	ABA	 
	Bank Name	 
	Bank Address	 
	Beneficiary Account Number (BNF)	 
	Beneficiary Account Name	 
	SWIFT Code	 

 

    [Signature Page to Warrant Exercise Agreement (Brio)]

     

    

 

[HOLDER SIGNATURE PAGE TO

WARRANT EXERCISE AGREEMENT]

 

IN WITNESS WHEREOF, the undersigned have
caused this Agreement to be duly executed by their respective authorized signatories as of the date first indicated above.

 

Name of Holder: Brio Capital Master Fund Ltd.

 

Signature of Authorized Signatory of Holder: /s/Shaye
Hirsch

 

Name of Authorized Signatory: Shaye Hirsch

 

Title of Authorized Signatory: Director

 

Date: May 14, 2018

 

Total Number of Series C Warrant Shares Underlying Series C
Warrant: 198,333

Revised Series C Warrant Exercise Price: $2.50

Aggregate Exercise Price to be Paid: $123,957.50

Number of Series C Warrant Shares to be Issued Upon Exercise: 49,583

 

Total Number of Series D Warrant Shares Underlying Series D
Warrant: 208,333

Revised Series D Warrant Exercise Price: $2.50

Aggregate Exercise Price to be Paid: $130,207.50

Number of Series D Warrant Shares to be Issued Upon Exercise: 52,083

 

Total Number of Series E Warrant Shares Underlying Series E
Warrant: 208,333

Revised Series E Warrant Exercise Price: $2.50

Aggregate Exercise Price to be Paid: $77,727.50

Number of Series E Warrant Shares to be Issued Upon Exercise: 31,091

 

Total Number of Series F Warrant Shares Underlying Series F
Warrant: 193,333

Revised Series F Warrant Exercise Price: $2.50

Aggregate Exercise Price to be Paid: $120,832.50

Number of Series F Warrant Shares to be Issued Upon Exercise: 48,333

 

DWAC Instructions for Warrant Shares:

 

____________________________

  

____________________________

 

____________________________

 

 

Replacement Warrants:

 

Number of Series C Warrant Shares at exercise price of $4.00
per share: 148,750

 

Number of Series D Warrant Shares at exercise price of $4.00
per share: 156,250

 

Number of Series E Warrant Shares at exercise price of $4.50
per share: 93,278

 

Number of Series F Warrant Shares at exercise price of $4.00
per share: 145,000

 

    [Signature Page to Warrant Exercise Agreement (Brio)]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00283-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00283-of-00352.parquet"}]]